The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...
Anti-PD1 immunotherapy improves outcomes for patients with metastatic cutaneous squamous cell carcinoma (cSCC). But we need to know more about who will, or will not, respond adequately.
except for 1 patient with end-stage renal disease undergoing hemodialysis who received sorafenib 200 mg daily. Two patients reported a history of previous treatment for AK and SCC before the ...
Sun Pharma to acquire Waltham, Massachusetts-based Checkpoint Therapeutics: Our Bureau, Mumbai Monday, March 10, 2025, 13:30 Hrs [IST] Sun Pharmaceutical Industries Limited and Ch ...
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
Anti-PD1 immunotherapy improves outcomes for patients with metastatic cutaneous squamous cell carcinoma (cSCC). But we need to know more about who will, or will not, respond adequately.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback